2026-01-04 - Analysis Report
Okay, here's a breakdown of the provided information for Eli Lilly and Co (LLY), with analysis following each section.

**1) Performance vs. S&P 500 (VOO)**

*   **Company Overview:** Eli Lilly and Co is a pharmaceutical company discovering, developing, and marketing pharmaceutical products.

*   **Cumulative Return (LLY):** 281.68%
*   **Cumulative Return (VOO):** 91.00%
*   **Divergence:**
    *   Current: 190.7
    *   Relative Divergence: 83.9

**Analysis:**

LLY has significantly outperformed the S&P 500 (VOO) over the period represented by the cumulative returns. The divergence of 190.7 indicates a large difference in performance. The relative divergence of 83.9 suggests that the current divergence is high compared to its historical range, indicating that the outperformance is near the upper end of its historical relative performance.

**Alpha, Beta Analysis:**

| Year       | CAGR    | MDD    | Alpha   | Beta  | Cap(B) |
|------------|---------|--------|---------|-------|--------|
| 2016-2018  | 37.0%  | 14.3%  | 33.0%  | 0.7   | 103.7 |
| 2017-2019  | 36.0%  | 14.7%  | 19.0%  | 0.7   | 117.8 |
| 2018-2020  | 30.0%  | 20.9%  | 10.0%  | 0.7   | 151.4 |
| 2019-2021  | 49.0%  | 20.9%  | 5.0%  | 0.7   | 247.6 |
| 2020-2022  | 59.0%  | 20.9%  | 60.0%  | 0.7   | 328.0 |
| 2021-2023  | 116.0%  | 18.0%  | 115.0% | 0.5   | 522.6 |
| 2022-2024  | 123.0%  | 27.0%  | 104.0% | 0.6   | 692.1 |
| 2023-2025  | 183.0%  | 29.9%  | 121.0% | 0.7   | 963.4 |

*   **CAGR (Compound Annual Growth Rate):**  The CAGR has consistently been high, with a significant acceleration in recent years.
*   **MDD (Maximum Drawdown):**  The MDD represents the largest peak-to-trough decline during the period. While increasing, they remain relatively controlled compared to the CAGR.
*   **Alpha:**  Alpha represents the excess return generated compared to the benchmark (S&P 500).  The high Alpha values indicate significant outperformance, especially in recent periods.
*   **Beta:** Beta measures the stock's volatility relative to the market. A Beta around 0.7 suggests that LLY is less volatile than the S&P 500.
*   **Cap(B):** Market Cap is consistently growing.

**Analysis:**

This table shows strong growth for LLY. The high CAGR and Alpha figures confirm the significant outperformance. The Beta of around 0.7 suggests that LLY is less volatile than the broader market. The consistently increasing market capitalization reflects investor confidence and growth. The recent years (2020-2025) show a dramatic increase in CAGR and Alpha, indicating significant recent growth and outperformance.

**2) Recent Stock Price Fluctuations**

*   **Close:** 1080.36
*   **Last-market:**  {'price': 1080.36, 'previousClose': 1074.68, 'change': 0.53}
*   **5-day SMA:** 1078.254
*   **20-day SMA:** 1046.905
*   **60-day SMA:** 968.3677

**Analysis:**

The stock price is currently above all three Simple Moving Averages (SMAs). This is generally considered a bullish signal. The 5-day SMA is above the 20-day SMA, which is above the 60-day SMA, further reinforcing the upward trend. The slight positive change from the previous close indicates a continuation of this trend.

**3) RSI, PPO, and Market Risk Indicator**

*   **MRI (Market Risk Indicator):** 0.8 (Medium Investment Recommended)
*   **RSI:** 76.97
*   **PPO:** -0.1559
*   **Hybrid Signal:** cash_0%_Buy 100% of cash
*   **Recent (20 days) relative divergence change:** 0.6 (+): 단기상승 (Short-term rise)
*   **Expected Return (%):** 47.3

**Analysis:**

*   **MRI:** The MRI suggests a medium investment recommendation, indicating a moderate level of risk.
*   **RSI:** An RSI of 76.97 indicates that the stock is currently overbought, which might suggest a potential pullback in the near future.
*   **PPO:** The PPO is negative, but close to zero, suggesting that the short-term moving average is slightly below the long-term moving average, but the difference is small.
*   **Hybrid Signal:** The "Buy 100% of cash" signal is very strong, suggesting a highly positive outlook.
*   **Recent Divergence Change:** The positive change in relative divergence over the last 20 days reinforces the short-term upward trend.
*   **Expected Return:** The expected return of 47.3% is exceptionally high, suggesting significant potential upside if held long-term.

**4) Recent News & Significant Events**

*   **[2026-01-04]** Eli Lilly and Company $LLY Shares Sold by NTV Asset Management LLC - MarketBeat
*   **[2025-12-22]** Jim Cramer Says Eli Lilly’s GLP-1 Pill Is “Going to Revolutionize Everything” - Yahoo Finance
*   **[2025-12-29]** Eli Lilly stock today: LLY inches up as weight-loss pill pricing, insider filing keep spotlight on obesity drugs - ts2.tech
*   **[2025-12-31]** Futures Fall; Seven Stocks Near Buy Points As 2026 Looms - Investor's Business Daily
*   **[2025-12-16]** Where Will Eli Lilly Be in 10 Years? - The Motley Fool
*   **[2025-12-26]** Eli Lilly (LLY) a Top Stock Split Candidate in 2026 - TipRanks

**Analysis:**

*   **GLP-1 Pill Hype:**  Jim Cramer's statement about the GLP-1 pill revolutionizing everything is a significant positive catalyst. Weight loss drugs are a major area of interest for investors, and positive commentary from influential figures can significantly boost the stock.
*   **Weight-Loss Pill Pricing:** News regarding weight-loss pill pricing indicates that this is a key factor influencing the stock's movement.
*   **Stock Split Potential:** The mention of a potential stock split in 2026 is generally seen as positive, as it can make the stock more accessible to retail investors.
*   **Institutional Selling:** The news of NTV Asset Management selling shares is a slightly negative signal, but the overall positive sentiment from other news sources likely outweighs this.

**4-2) Analyst Opinions**

*   **Analyst Consensus:**
    *   Key: Buy
    *   Mean (1=StrongBuy~5=Sell): 1.70 (~Buy)
    *   Opinions: 27
    *   Target Price (avg/high/low): 1093.22 / 1500.00 / 770.00

**Analysis:**

The analyst consensus is strongly bullish, with a "Buy" rating and a mean score of 1.70. The average target price of 1093.22 is slightly above the current price, suggesting further upside potential. The high target of 1500.00 indicates that some analysts are very optimistic about the stock's future.

**5) Recent Earnings Analysis**

| 날짜       | EPS  | 매출        |
|------------|------|-------------|
| 2025-10-30 | 6.22 | 17.60 B$   |
| 2025-08-07 | 6.3  | 15.56 B$   |
| 2025-05-01 | 3.07 | 12.73 B$   |
| 2024-10-30 | 1.08 | 11.44 B$   |
| 2025-10-30 | 1.08 | 11.44 B$   |

**Analysis:**

*   **Strong Growth:** Both EPS and Revenue have shown significant growth over the reported quarters.
*   **Recent Performance:** The most recent quarters (2025-10-30 and 2025-08-07) show particularly strong EPS figures.
*   **Inconsistencies:** The entry for 2025-10-30 and 2024-10-30 are the same but probably an error.

**6) Financial Information**

**Revenue and Profitability:**

| Quarter      | Revenue   | Profit Margin |
|--------------|-----------|---------------|
| 2025-09-30   | $17.60B   | 82.91%       |
| 2025-06-30   | $15.56B   | 84.27%       |
| 2025-03-31   | $12.73B   | 82.53%       |
| 2024-12-31   | $13.53B   | 82.24%       |
| 2024-09-30   | $11.44B   | 81.02%       |

**Capital and Profitability:**

| Quarter      | Equity    | ROE      |
|--------------|-----------|----------|
| 2025-09-30   | $23.79B   | 23.46%   |
| 2025-06-30   | $18.27B   | 30.98%   |
| 2025-03-31   | $15.76B   | 17.50%   |
| 2024-12-31   | $14.19B   | 31.07%   |
| 2024-09-30   | $14.24B   | 6.81%    |

**Analysis:**

*   **Revenue Growth:**  Consistent revenue growth is evident over the quarters.
*   **High Profit Margins:**  The profit margins are exceptionally high, consistently above 80%. This indicates strong pricing power and efficient operations.
*   **Equity Growth:**  Equity is steadily increasing, reflecting the company's profitability and retained earnings.
*   **Strong ROE:** The Return on Equity (ROE) is high, suggesting that the company is effectively using shareholders' equity to generate profits.

**7) Comprehensive Analysis (Summary)**

Eli Lilly (LLY) exhibits a very strong and bullish profile:

*   **Outperformance:**  Significantly outperforms the S&P 500.
*   **Growth:** High CAGR, excellent recent revenue and earnings growth, and increasing market capitalization demonstrate robust growth.
*   **Profitability:**  Exceptional profit margins and ROE indicate efficient operations and strong profitability.
*   **Momentum:** Bullish technical indicators (SMA relationships), positive short-term divergence change, and strong buy signal.
*   **Catalysts:** Positive news flow related to GLP-1 pills, potential stock split, and favorable analyst ratings.
*   **Risks:**  Slightly overbought RSI, potential for a pullback, and institutional selling.

**Overall, the data suggests that Eli Lilly is a strong investment. The company is growing rapidly, highly profitable, and has positive momentum. While there are some potential risks, the overall outlook is very positive.**


**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.